Behavioral and Pharmacological Reconsolidation Interference in Misophonia (Miso Prop)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05928689 |
Recruitment Status :
Recruiting
First Posted : July 3, 2023
Last Update Posted : December 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Misophonia | Drug: Propranolol Hydrochloride tablet Behavioral: Reminder Behavioral: Counterconditioning Drug: Placebo | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The study team will measure reactivity to misophonia-related cues following either a pharmacological manipulation via a 40 mg propranolol tablet or behavioral manipulation via counterconditioning. The study team predicts that participants with misophonia who experience a reminder (reactive a misophonia memory) and receive the pharmacological or behavioral manipulation, will show reduced reactivity to misophonia cues. Other groups that undergo one of these components alone (reminder only, drug only, counterconditioning only) will continue to show heightened reactivity to misophonia cues. |
Masking: | Triple (Participant, Care Provider, Investigator) |
Masking Description: | This study is multi-arm and single-site randomized study that is placebo-controlled and single- and double-blinded depending on the condition assignment. Some groups will experience reminders, or short exposures to misophonia-related cues. Some groups will take the study intervention, propranolol hydrochloride (or matching placebo) oral tablets, and some will undergo counterconditioning, by presenting the misophonia cues with monetary rewards (in a continuous reinforcement schedule with fixed monetary amounts). |
Primary Purpose: | Other |
Official Title: | Misophonia-Related Memory Modification Using Reconsolidation Mechanisms: Pharmacological and Behavioral Manipulation |
Actual Study Start Date : | June 2, 2023 |
Estimated Primary Completion Date : | August 2024 |
Estimated Study Completion Date : | August 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Memory Reminder followed by Propranolol Hydrochloride
This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a propranolol hydrochloride tablet.
|
Drug: Propranolol Hydrochloride tablet
Single dose of 40 mg propranolol tablet Behavioral: Reminder Reactivation of misophonia trigger memory |
Placebo Comparator: Memory reminder followed by Placebo
This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a placebo tablet.
|
Behavioral: Reminder
Reactivation of misophonia trigger memory Drug: Placebo Matching placebo tablet |
Experimental: No memory reminder followed by Propranolol Hydrochloride
This arm aims to have 30 participants with a pharmacological manipulation. They will not receive a reminder to reactivate their memory of a misophonia sound and only receive a propranolol hydrochloride tablet.
|
Drug: Propranolol Hydrochloride tablet
Single dose of 40 mg propranolol tablet |
Experimental: Memory reminder followed by counterconditioning
This arm aims to have 30 participants with a behavioral manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger and then will undergo counterconditioning.
|
Behavioral: Reminder
Reactivation of misophonia trigger memory Behavioral: Counterconditioning Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards. |
Experimental: No memory reminder followed by counterconditioning
This arm aims to have 30 participants with a behavioral manipulation. They will not receive a reminder to reactivate their memory of a misophonia trigger and then undergo counterconditioning.
|
Behavioral: Counterconditioning
Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards. |
- Change in average Galvanic skin response based on deflections of a wave [ Time Frame: Baseline and after 6 hours ]Using galvanic skin response based on deflections of a wave, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. A greater deflection indicates greater sympathetic nervous system arousal.
- Change in average heart rate [ Time Frame: Baseline and after 6 hours ]Using heart rate measurement, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. Reduced heart rate will indicate manipulation efficacy
- Change in Approach-Avoidance test [ Time Frame: Baseline and after 6 hours ]Using an approach-avoidance test, the difference between the monetary amounts earned before and after the pharmacological or behavioral manipulation will be measured. The minimum monetary amount earned is $0 and the maximum monetary amount earned is $23. A higher monetary amount earned indicates greater approach towards an avoidant cue. The difference in monetary amounts across conditions will be compared.
- Change in Approach-Avoidance test [ Time Frame: about 1 week later ]Using an approach-avoidance test, the difference between the monetary amounts earned before and after the pharmacological or behavioral manipulation will be measured. The minimum monetary amount earned is $0 and the maximum monetary amount earned is $23. A higher monetary amount earned indicates greater approach towards an avoidant cue. The difference in monetary amounts across conditions will be compared.
- Change in Approach-Avoidance test [ Time Frame: Baseline and 1 month later ]Using an approach-avoidance test, the difference between the monetary amounts earned before and after the pharmacological or behavioral manipulation will be measured. The minimum monetary amount earned is $0 and the maximum monetary amount earned is $23. A higher monetary amount earned indicates greater approach towards an avoidant cue. The difference in monetary amounts across conditions will be compared.
- Change in decision making task [ Time Frame: Baseline and after 6 hours ]
Using a decision making task based on choice behavior (choosing the correct machine more often), the study team will fit computational models to understand reactivity to misophonia-related cues across conditions.
The study team will measure a difference in the task responses after the pharmacological or behavioral manipulation. Measures will include learning rate, and a link between prediction error and self-reported mood. The scores across conditions will be compared.
- Change in decision making task [ Time Frame: Baseline and about 1 week ]
Using a decision making task based on choice behavior (choosing the correct machine more often), the study team will fit computational models to understand reactivity to misophonia-related cues across conditions.
The study team will measure a difference in the task responses after the pharmacological or behavioral manipulation. Measures will include learning rate, and a link between prediction error and self-reported mood. The scores across conditions will be compared.
- Change in decision making task [ Time Frame: Baseline and 1 month later ]
Using a decision making task based on choice behavior (choosing the correct machine more often), the study team will fit computational models to understand reactivity to misophonia-related cues across conditions.
The study team will measure a difference in the task responses after the pharmacological or behavioral manipulation. Measures will include learning rate, and a link between prediction error and self-reported mood. The scores across conditions will be compared.
- Change in Average Galvanic skin response based on deflections of a wave [ Time Frame: about 1 week later ]Using galvanic skin response based on deflections of a wave, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. A greater deflection indicates greater sympathetic nervous system arousal.
- Change in Average Galvanic skin response based on deflections of a wave [ Time Frame: about 1 month later ]Using galvanic skin response based on deflections of a wave, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. A greater deflection indicates greater sympathetic nervous system arousal.
- Change in average heart rate [ Time Frame: about 1 week later ]Using heart rate measurement, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. Reduced heart rate will indicate manipulation efficacy
- Change in average heart rate [ Time Frame: about 1 month later ]Using heart rate measurement, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. Reduced heart rate will indicate manipulation efficacy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
- Must be between the ages of 18 - 55.
- Must be fluent in English since the study's instructions, surveys, and tasks will be in English
Exclusion Criteria:
- Disability or medical condition that prohibits completion of study. Participants must be able to complete all study procedures to ensure optimal conditions for data analysis.
- CNS disease, such as history of brain abnormalities (e.g., neoplasms, subarachnoid cysts), cerebrovascular disease, infectious disease (e.g., abscess), or other neurological disease, history of head trauma (defined as loss of consciousness>3 min), or history of seizures without a resolved etiology. CNS disease and drugs that act in the peripheral or central nervous system are likely to have effects on patterns of neural activity. We wish to minimize confounding variables.
- Recently used drugs of abuse.
- Pregnancy. The risks associated with neither propranolol exposure during gestation have been studied extensively. We wish to safeguard the health of potential participants and their children.
- Lactation. Propranolol is excreted in human breast-milk, and its impact on infant development has not been studied. We wish to safeguard the health of potential participants and their children.
- Regular use of medication metabolized in the CYP2D6, 1A2, or 2C19 pathways. Drugs that are metabolized in the same pathway as propranolol may increase its efficacy or toxicity. We wish to safeguard the health of participants.
- Blood pressure over 150/100 or under 100/60 (applicable for either systolic or diastolic measures) and any hypertension requiring medication. Propranolol is known to pose additional risk to individuals with a number of medical conditions. We wish to safeguard the health of our participants.
- Pulse over 100 or under 55.
- History of cardiovascular illness such as cardiac arrhythmia, coronary heart disease or any cardiac dysfunction that requires medication.
- Active respiratory illness including bronchospastic pulmonary disease and chronic obstructive pulmonary disease
- Diabetes mellitus.
- Other medical conditions that make it unsafe to take propranolol (e. g. allergy to propranolol).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05928689
Contact: Alissa Chen, BA | 781-467-6462 | alissa.chen@mssm.edu |
United States, New York | |
Icahn School of Medicine at Mount Sinai | Recruiting |
New York, New York, United States, 10029 | |
Contact: Alissa Chen, BA alissa.chen@mssm.edu |
Principal Investigator: | Daniela Schiller, PhD | Icahn School of Medicine at Mount Sinai | |
Principal Investigator: | James Murrough, MD, PhD | Icahn School of Medicine at Mount Sinai | |
Principal Investigator: | Laili Soleimani, MD, Msc | Icahn School of Medicine at Mount Sinai |
Responsible Party: | Daniela Schiller, Professor of Neuroscience and Psychiatry, Icahn School of Medicine at Mount Sinai |
ClinicalTrials.gov Identifier: | NCT05928689 |
Other Study ID Numbers: |
STUDY-22-01280 |
First Posted: | July 3, 2023 Key Record Dates |
Last Update Posted: | December 12, 2023 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The study team will publicly share analyzed statistical summaries which are sufficient for data assessment, reanalysis, and meta-analysis, and reproduction of figures. |
Time Frame: | 2 months after publication |
Access Criteria: | Open access with no restrictions |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Propranolol Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents |